leisure time -WSS

leisure time

author：leisure time 2025-10-01 17:35:14 - browse：848

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Carbon Health diabetes program, a test of data

WSS

Readout Newsletter: Zepbound, Valneva's vaccine, and more

RSV shot was 90% effective at preventing hospitalizations in kids

Sen. Paul opposes bill to ban Chinese biotechs

How to bring more disabled researchers into academia

A letter from the executive editor: STAT UnitedHealth investigation

Just how do doctors, lawmakers, and the public define abortion?

entertainment

leisure time

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Hepatitis C has a cure — but many Americans still lack access to it

Type 2 diabetes prevention programs work at large scale: study

United colonoscopy coverage change 'may cost lives,' doctors say

Medicare’s new pay boost for primary care is angering specialists

Malaria cases in Florida and Texas: Here’s what you need to know

Weight loss drugs should be covered by insurers, AMA says

Medicare details structure of new drug price negotiation program

Ventyx halts psoriasis drug development after lackluster trial results

focus

Weight loss drugs should be covered by insurers, AMA says

Change Healthcare cyberattack prompts Medicare loan program

Type 2 diabetes prevention programs work at large scale: study

Change Healthcare cyberattack prompts Medicare loan program

What is STAT's opinion section for?

Medicare’s new pay boost for primary care is angering specialists

focus

knowledge

explore

entertainment